Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
August 2017
-
Press Release
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer… -
Press Release
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in… -
Press Release
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is… -
Press Release
Novartis appoints Bertrand Bodson as Chief Digital Officer
New leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury'… -
Press Release
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Approval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole… -
Press Release
Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistant
Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la… -
Press Release
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first… -
Press Release
Novartis und Medicines for Malaria Venture starten in Afrika eine Patientenstudie mit KAF156, einem neuartigen Wirkstoff gegen multiresistente Malaria
Der Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen.…
July 2017
-
Press Release
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is… -
Press Release
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first… -
Press Release
Die Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer Produkte
Der Nettoumsatz liegt auf Vorjahresniveau (0% kWk[1], -2% USD), wobei die Wachstumstreiber die Einbussen durch Generika von Glivec/Gleevec wettmachen: Cosentyx (USD 490 Millionen, +90% kWk)… -
Press Release
Les résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateurs
Chiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec: Cosentyx (…